As of August 19, 2023, four CD47 targeted treatment trials for ovarian cancer were registered in the US National Clinical Trials Registry (NCT), including BI 765063 (an antibody antagonist of SIRPα formerly known as OSE-172, NCT04653142), which exhibited potential effectiveness and good tolerance in its preliminary report without dose-limiting toxicities in patients with ovarian cancer (Table 3) (31). Here, SIRPA is linked to ovarian carcinoma.